Vitamin D deficiency is associated with increased risk of cardiovascular mortality and chronic kidney disease (CKD) progression in patients with early-stage disease, according to research published online May 11. Endocrinological Research Journal.
Yanhong Lin of Southern Medical University in Guangzhou, China, and his colleagues found that 25-hydroxyvitamin D (25[OH]D) Deficiencies in cardiovascular mortality and renal outcomes in patients with early-stage CKD. The analysis included 9,229 adult patients with CKD (stages 1-3) from 19 medical centers across China (January 2000 to May 2021).
Researchers found that patients with 25(OH)D ≥20 ng/mL had a significantly higher risk of cardiovascular mortality (hazard ratio 1.90) and CKD progression (hazard ratio 2.20) and a lower annual mortality rate. I found it to be expensive. Patients with serum 25(OH)D <10 ng/mL have a decreased estimated glomerular filtration rate (estimated, -7.87 percent per year).
“In conclusion, 25(OH)D deficiency was common in patients with early-stage CKD,” the authors wrote. “Vitamin D status should be carefully monitored in patients with early CKD. To determine whether timely vitamin D supplementation can prevent cardiovascular events and loss of renal function in patients with early CKD and 25(OH) Well-designed, randomized clinical trials are needed for ‘D deficiency. ”
For more information:
Y. Lin et al. Association of serum 25-hydroxyvitamin D with cardiovascular mortality and renal outcomes in early-stage CKD patients. Endocrinological Research Journal (2024). DOI: 10.1007/s40618-024-02383-6
